US Markets impressive bounce back; Finance Minister assures one-time restructuring of loans soon
Video description:
1. In a chat with ET Now, Nikunj Dalmia said that the market is still giving entry point but caution from the side of the investors as well as stockbrokers is still being maintained. The fluctuations in the market yesterday was not wide swaying but was consolidating and smooth. The good performance of Nifty adds to the recovery of the economy after COVID-19 lockdown and is a step to a better market graph. The retail interest is high at the moment. Most interestingly, the US market yesterday bounced back in a very impressive manner. Currently, the renewed focus at the moment is on the auto industry and the aviation sector. Watch the video to know more! 2. Finance Minister Nirmala Sitharaman has assured that the finance ministry is in talks with the Reserve Bank of India (RBI) on restructuring the loan facilities in a one-time process. This comes amid the fact that the loans have become increasingly burdened for the public and the demand for respite for the same has been in the light. The loans are being discussed with the Reserve Bank of India (RBI)for restructuring loans in the tourism, hospitality, and aviation sectors which are also the ones that have faced the worse impact due to the COVID-19 pandemic in the country. 3.Pricing situation currently stable in the US. Focusing more on complex generics right now. Complex injectables, inhalers are key growth areas. India's pharma remains largely underpenetrated. Biosimilars & complex drugs the next frontier in Indian pharma. Pharma has 3 Pillars of Growth - US Generics market, under-penetrated domestic market & other emerging markets. The growth areas in the Pharma sector globally have been Complex Injectables, Inhalers & Biosimilars. There is a huge growth opportunity in the domestic market, says Ramesh Swaminathan, ED, Global CFO, Head - Corporate Affairs, Lupin. Ramesh Swaminathan, Lupin talks about the pricing trend in the US markets and the 3 biggest pillars of growth for the Pharma sector. 4. Brewers in low spirits after COVID hurts Q4 sales volumes. The Coronavirus weighs on UBL's earnings. A dull year for brewing companies? Recovery seen in May, June? Are doorstep services, a reason to cheer? Shekhar Ramamurthy, MD, United Breweries joins in on The Market to discuss how they plan to regain the lost earnings. United Breweries’ Q4FY20 earnings report saw net revenue at Rs 1425.1 crore vs Rs 1630.4 crore, down 12.6% and PAT at Rs 41.8 crore vs Rs 68.9 crore, down 39.3% and EBITDA at Rs 133 crore vs Rs 172.3 crore, down 22.8% with margins at 9.3% vs 10.6%. Here’s a look at the highlights from their Q4 earnings that have been affected due to the COVID-19 crisis. Pre-COVID Volumes Slipped By 6%. The lockdown volumes down by 21%. Eastern markets see a huge decline. The positive price mix has aided gross margins. Watch! Subscribe To ET Now For Latest Updates On Stocks, Business, Trading | ► https://goo.gl/SEjvK3 Subscribe Now To Our Network Channels :- Times Now : http://goo.gl/U9ibPb The NewsHour Debate : http://goo.gl/LfNgFF To Stay Updated Download the Times Now App :- Android Google Play : https://goo.gl/zJhWjC Apple App Store : https://goo.gl/d7QBQZ Social Media Links :- Twitter - http://goo.gl/hA0vDt Facebook - http://goo.gl/5Lr4mC G+ - http://goo.gl/hYxrmj Website - www.etnownews.com
via https://youtu.be/MLuJA9DhPho
We do not own the video this is just a player link and it could contain by other parties.
Watch youtube video here: the best video collection
No comments:
Post a Comment